Vigonvita Life Sciences plans multiple-dose Phase 1 tablet trial for VV261
The Chinese sponsor is moving VV261 into a 16-subject ascending-dose safety and pharmacokinetics study ahead of an August 2026 start, its second Phase 1 trial for the oral small molecule.
Executive Summary
- Vigonvita Life Sciences has registered a new Phase 1 trial testing multiple ascending doses of its oral tablet VV261, expanding the drug's clinical program beyond an earlier single-dose study.
- The trial is built entirely around pharmacokinetics and tolerability, the standard early groundwork for a small molecule before any efficacy testing begins.
- The sponsor has a clean execution record across its broader trial portfolio, a fact that speaks to operational reliability rather than to VV261's prospects specifically.
- The drug's target and mechanism are not established in available records, leaving the program's competitive position undefined until more is disclosed.
The new trial
Vigonvita Life Sciences added NCT07710326 to the registry on July 17, 2026, a Phase 1 study titled "Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV261 Tablets". The trial plans to enroll 16 subjects in China, with a randomized, double-masked, two-arm design comparing VV261 against placebo. It is set to start August 1, 2026, with a primary completion date of November 30, 2026, a roughly four-month window consistent with a short ascending-dose pharmacokinetic study. NCT07710326Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV261 TabletsNCT07710326
What the trial measures
The registered primary outcomes are pharmacokinetic parameters: area under the plasma concentration curve (AUC0-t and AUC0-infinity), maximum and trough plasma concentrations (Cmax, Ctrough), clearance, volume of distribution, half-life, and time to peak concentration, tracked from baseline through 72 hours after the last dose. The trial also tracks treatment-emergent adverse events through seven days post-dose as a primary outcome. This is a dose-escalation safety and exposure study, not an efficacy trial: its information value lies in characterizing how VV261 behaves in the body across ascending doses and whether tolerability holds as dose increases. NCT07710326Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV261 TabletsNCT07710326
The broader program
VV261 already has one other trial in the registry, a single-dose safety, tolerability, and pharmacokinetics study enrolling 58 Chinese healthy volunteers that remains recruiting with a primary completion date of June 30, 2026. The new multiple-ascending-dose trial is the logical next step after that single-dose work, sequencing standard early clinical development for an oral small molecule. Both trials sit in Phase 1 and neither is registrational. NCT07710326Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV261 TabletsNCT07710326
Sponsor track record
Vigonvita Life Sciences has completed 25 of 25 trials in its overall portfolio with no terminations recorded, and currently runs eight recruiting studies and two not-yet-recruiting studies including this one. That track record speaks to the sponsor's operational execution, not to any signal about VV261's clinical prospects, since none of that history involves VV261 efficacy data. VV261's target, mechanism, and indication are not established in available records, so no claim about the drug's competitive position, novelty, or overlap with other programs can be made at this stage.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.